The Microbicide Trials Network (MTN, 2006-2021) was a United States government-funded research organization working in the field of microbicides for sexually transmitted diseases.[1][2] The MTN focused on research into microbicides which would prevent HIV infection. The MTN was a member of HANC. After its closure, partner organization HIV Prevention Trials Network took control of its projects.[2]
Research edit
The MTN's notable research included various clinical trials.
The results of the CAPRISA 004 trial inspired the research of the MTN and the microbicide field.[3]
The Vaginal and Oral Interventions to Control the Epidemic (VOICE) found a vaginal gel containing an anti-HIV drug to be ineffective at preventing HIV transmission..[4]
The HOPE study tested dapivirine vaginal rings for HIV prevention in 1,456 study participants at 14 sites in Malawi, South Africa, Uganda and Zimbabwe.[5]
References edit
- ^ Hillier, Sharon (30 November 2021). "Thank you for these past 15 years". www.mtnstopshiv.org. Microbicide Trials Network.
- ^ a b Buhl, Larry (4 January 2021). "NIH Restructures HIV Clinical Trial Networks; AIDS Director Touts Milestones". thebodypro.com. HealthCentral.
- ^ Alcorn, Keith (19 July 2010). "Tenofovir-based microbicide gel reduces risk of infection for women by 39%". aidsmap.com. Aidsmap.
- ^ Cohen, Jon (28 November 2011). "Baffling Failure of Vaginal Gel Laced With Anti-HIV Drug - ScienceNOW". news.sciencemag.org. Archived from the original on 6 February 2012. Retrieved 6 March 2012.
- ^ "Most women use vaginal ring for HIV prevention in open-label study". National Institutes of Health (NIH). 23 July 2019.